A Real world study comparing the impact of renal function on clinical outcomes associated with warfarin versus rivaroxaban treatment in patients with non-valvular atrial fibrillation (NVAF)

Trial Profile

A Real world study comparing the impact of renal function on clinical outcomes associated with warfarin versus rivaroxaban treatment in patients with non-valvular atrial fibrillation (NVAF)

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin
  • Indications Atrial fibrillation
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 May 2017 Results presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 22 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top